Skip to main content
SpringerLink
Log in

What Are the Long-Term Toxicities to Be Controlled and Treated?

  • Chapter
Book cover Diagnosis and Management of Testicular Cancer

  • 919 Accesses

Abstract

The combination of young age at diagnosis, high survival rate, and rising incidence increases the cohort of TC survivors (TCS). Although TCS have an estimated normal life expectancy, mortality rates among TCS may exceed rates among the general population [1, 2]. In addition to an increased risk of dying from recurrent TC or a second cancer, TCS have a 6 % increased risk of mortality from non-cancer causes, including infections, cardiovascular disease (CVD), and respiratory disease after cisplatin-based chemotherapy compared with the general population [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer. 2004;90(3):607–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007;99(7):533–44.

    Article  PubMed  Google Scholar 

  3. Hemminki K, Liu H, Sundquist J. Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann Oncol. 2010;21(7):1546–51.

    Article  CAS  PubMed  Google Scholar 

  4. Richiardi L, Scelo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer. 2007;120(3):623–31.

    Article  CAS  PubMed  Google Scholar 

  5. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, van Leeuwen FE, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89(19):1429–39.

    Article  CAS  PubMed  Google Scholar 

  6. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354–65.

    Article  PubMed  Google Scholar 

  7. van den Belt-Dusebout A, de Wit R, Gietema JA, Horenblas S, Louwman MWJ, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370–8.

    Article  PubMed  Google Scholar 

  8. van Leeuwen FE, Stiggelbout AM, Vandenbeltdusebout AW, Noyon R, Eliel MR, Vankerkhoff EHM, et al. second cancer risk following testicular cancer – a follow-Up-study of 1,909 patients. J Clin Oncol. 1993;11(3):415–24.

    PubMed  Google Scholar 

  9. Wanderas EH, Fossa SD, Tretli S. Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer. 1997;33(2):253–62.

    Article  CAS  PubMed  Google Scholar 

  10. Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014;110(1):256–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fossa SD. Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953–2007). Int J Cancer. 2011;129(12):2867–74.

    Article  CAS  PubMed  Google Scholar 

  12. Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92(14):1165–71.

    Article  CAS  PubMed  Google Scholar 

  13. Howard R, Gilbert E, Lynch CF, Hall P, Storm H, Holowaty E, et al. Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients. Ann Epidemiol. 2008;18(5):416–21.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Bokemeyer C, Schmoll HJ. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol. 1995;13(1):283–92.

    CAS  PubMed  Google Scholar 

  15. Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2013;30(31):3807–14.

    Article  Google Scholar 

  16. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617–24.

    Article  CAS  PubMed  Google Scholar 

  17. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14(1):91–6.

    Article  PubMed  Google Scholar 

  18. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med. 1990;11(1):1–20.

    CAS  PubMed  Google Scholar 

  19. Culine S, Kramar A, Theodore C, Geoffrois L, Chevreau C, Biron P, et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol. 2008;26(3):421–7.

    Article  CAS  PubMed  Google Scholar 

  20. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19(6):1629–40.

    PubMed  Google Scholar 

  21. Loehrer Sr PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13(2):470–6.

    PubMed  Google Scholar 

  22. Culine S, Kerbrat P, Kramar A, Theodore C, Chevreau C, Geoffrois L, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917–24.

    Article  CAS  PubMed  Google Scholar 

  23. Haugnes HS, Aass N, Fossa SD, Dahl O, Brydoy M, Aasebo U, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol. 2009;27(17):2779–86.

    Article  PubMed  Google Scholar 

  24. Schunemann HJ, Dorn J, Grant BJ, Winkelstein Jr W, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118(3):656–64.

    Article  CAS  PubMed  Google Scholar 

  25. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58(5):388–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513–23.

    Article  CAS  PubMed  Google Scholar 

  27. van den Belt-Dusebout A, Nuver J, de Wit R, Gietema JA, Huinink WWT, Rodrigus PTR, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006;24(3):467–75.

    Article  PubMed  Google Scholar 

  28. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649–57.

    Article  PubMed  Google Scholar 

  29. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30(30):3752–63.

    Article  PubMed  Google Scholar 

  30. Smith Jr SC, Collins A, Ferrari R, Holmes Jr DR, Logstrup S, McGhie DV, et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). Eur Heart J. 2012;33(23):2910–6.

    Article  PubMed  Google Scholar 

  31. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.

    Article  PubMed  Google Scholar 

  32. Teutsch C, Lipton A, Harvey HA. Raynauds-phenomenon as a side-effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep. 1977;61(5):925–6.

    CAS  PubMed  Google Scholar 

  33. Adoue D, Arlet P. Bleomycin and Raynaud’s phenomenon. Ann Intern Med. 1984;100(5):770.

    Article  CAS  PubMed  Google Scholar 

  34. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13–14):2229–38.

    Article  CAS  PubMed  Google Scholar 

  35. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynauds-phenomenon – a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95(3):288–92.

    Article  CAS  PubMed  Google Scholar 

  36. van Basten JP, Jonker-Pool G, van Driel MF, Sleijfer DT, Droste JH, van de Wiel HB, et al. Sexual functioning after multimodality treatment for disseminated nonseminomatous testicular germ cell tumor. J Urol. 1997;158(4):1411–6.

    Article  PubMed  Google Scholar 

  37. Oldenburg J, Fossa SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006;15(5):791–800.

    Article  PubMed  Google Scholar 

  38. Brydoy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101(24):1682–95.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007;5(1):70.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012;30(3):300–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2011;(2):CD005228.

    Google Scholar 

  42. Bauer CA, Brozoski TJ. Cochlear structure and function after round window application of ototoxins. Hear Res. 2005;201(1–2):121–31.

    Article  CAS  PubMed  Google Scholar 

  43. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77(8):1355–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Osanto S, Bukman A, Vanhoek F, Sterk PJ, Delaat JAPM, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992;10(4):574–9.

    CAS  PubMed  Google Scholar 

  45. Hansen SW, Groth S, Daugaard G, Rossing N, Rorth M. Long-term effects on renal-function and blood-pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ-cell cancer. J Clin Oncol. 1988;6(11):1728–31.

    CAS  PubMed  Google Scholar 

  46. Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol. 2002;13(2):222–8.

    Article  CAS  PubMed  Google Scholar 

  47. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer. 1999;83(6):866–9.

    Article  CAS  PubMed  Google Scholar 

  48. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25(1):47–58.

    Article  CAS  PubMed  Google Scholar 

  49. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010;102(15):1114–30.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Astor BC, Hallan SI, Miller III ER, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol. 2008;167(10):1226–34.

    Article  PubMed  Google Scholar 

  51. Perry DJ, Weiss RB, Taylor HG. Enhanced bleomycin toxicity during acute-renal-failure. Cancer Treat Rep. 1982;66(3):592–3.

    CAS  PubMed  Google Scholar 

  52. Bennett WM, Pastore L, Houghton DC. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep. 1980;64(8–9):921–4.

    CAS  PubMed  Google Scholar 

  53. Sprauten M, Brydoy M, Haugnes HS, Cvancarova M, Bjoro T, Bjerner J, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol. 2014;32(6):571–8.

    Article  CAS  PubMed  Google Scholar 

  54. Haring R, Volzke H, Steveling A, Krebs A, Felix SB, Schofl C, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J. 2010;31(12):1494–501.

    Article  CAS  PubMed  Google Scholar 

  55. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–41.

    Article  CAS  PubMed  Google Scholar 

  56. Svartberg J, Schirmer H, Medbo A, Melbye H, Aasebo U. Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromso study. Eur J Epidemiol. 2007;22(2):107–12.

    Article  CAS  PubMed  Google Scholar 

  57. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–27.

    Article  CAS  PubMed  Google Scholar 

  59. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–37.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Loge JH, Ekeberg O, Kaasa S. Fatigue in the general Norwegian population: normative data and associations. J Psychosom Res. 1998;45:53–65.

    Article  CAS  PubMed  Google Scholar 

  62. Fosså SD, Dahl AA, Loge JH. Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol. 2003;21(7):1249–54.

    Article  PubMed  Google Scholar 

  63. Orre IJ, Murison R, Dahl AA, Ueland T, Aukrust P, Fossa SD. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav Immun. 2009;23(6):868–74.

    Article  CAS  PubMed  Google Scholar 

  64. Sprauten M, Haugnes HS, Brydoy M, Tandstad T, Langberg CW, Bjoro T, et al. Fatigue in relation to treatment and gonadal function in a population-based sample of 796 testicular cancer survivors 12 and 19 years after treatment. J Clin Oncol. 2014;32(5s):abstract 4564.

    Google Scholar 

  65. Demark-Wahnefried W, Jones LW. Promoting a healthy lifestyle among cancer survivors. Hematol Oncol Clin North Am. 2008;22(2):319–42, viii.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005;23(24):5814–30.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Akershus University Hospital, Lorenskog and Oslo University Hospital, Lørenskog, Norway

    J. Oldenburg MD, PhD

  2. Department of Oncology, University Hospital of North Norway, Tromso, Norway

    H. S. Haugnes

  3. Department of Oncology, Oslo University Hospital, Oslo, Norway

    S. D. Fosså

Authors
  1. J. Oldenburg MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. S. Haugnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. D. Fosså
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Oldenburg MD, PhD .

Editor information

Editors and Affiliations

  1. Kliniken Essen-Mitte, Klinik für Urologie, Essen, Germany

    Susanne Krege

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Oldenburg, J., Haugnes, H.S., Fosså, S.D. (2015). What Are the Long-Term Toxicities to Be Controlled and Treated?. In: Krege, S. (eds) Diagnosis and Management of Testicular Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-17467-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17467-9_11

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17466-2

  • Online ISBN: 978-3-319-17467-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation